CBD and fibromyalgia: what the research says in 2026, without shortcuts

Fibromyalgia combines persistent widespread pain, fatigue and sleep disturbance. According to the INSERM collective expert review published in October 2020, it concerns around 1.6% of the population, with a clear female predominance. The same report notes that its management "is not codified" and most often remains symptomatic.

In 2024 the Haute Autorité de santé opened a scoping exercise on the diagnosis and therapeutic strategy for fibromyalgia — a sign that the French care pathway is being updated. This context explains why many people explore complementary avenues, CBD among them.

Three levels of evidence need to be distinguished, from the oldest to the most recent.

The pharmacology study by van de Donk, published in Pain in 2019, tested inhaled pharmaceutical cannabis in 20 women with fibromyalgia. It found no effect on spontaneous pain, and an unexpected result: cannabidiol "increased THC plasma concentrations but decreased THC-induced analgesic effects". CBD therefore does not improve analgesia there; it reduces it.

A systematic review published in Biomedicines in 2023 brought together nine studies (564 patients). Only one of the four randomised trials showed an effect on pain that differed from placebo. The authors conclude that there is "low quality" evidence of a short-term reduction in pain — a cautious finding, far from a demonstration.

This is the current headline. The largest and most recent trial, published in the Annals of the Rheumatic Diseases in 2026, compared CBD (50 mg per day) with placebo in 200 patients over 24 weeks. At week 24, the change in pain was −0.4 with CBD versus −1.1 with placebo, a difference in favour of placebo. The authors write that their results "do not support CBD at 50 mg per day as an analgesic adjunct in patients with fibromyalgia".

A negative result is not a non-result: it is the most robust piece of data available today, and it calls for caution in the face of promises. As with CBD and migraine, serious reviews call for the hoped-for to be distinguished from the proven.

A common confusion needs to be avoided. Medical cannabis, dispensed on prescription, is one thing; freely sold CBD wellness products are another. The French medical cannabis trial, monitored by the ANSM, covered five indications: refractory neuropathic pain, certain severe drug-resistant epilepsies, cancer-related symptoms, palliative situations and painful spasticity. Fibromyalgia is not among them.

In 2026, the scheme is moving towards a regulated roll-out, with an opinion from the HAS expected. But none of this concerns over-the-counter CBD products, which are not medicines and cannot claim any therapeutic effect.

We can neither state nor suggest that CBD relieves fibromyalgia: the law prohibits it for a CBD product, and the state of the science would not allow it either. What we offer are flowers, resins and cosmetics analysed batch by batch, presented for what they are. For a cosmetic use aimed at comfort, our article on the cosmetic balm and everyday joint comfort stays within this strict framework.

If you live with fibromyalgia, the right approach goes through your doctor, the only person able to assess your situation and your treatment.

How many people have fibromyalgia in France?

According to the INSERM collective expert review published in 2020, fibromyalgia affects around 1.6% of the French population, with a clear female predominance. The report stresses that its management remains little codified and most often symptomatic.

Is medical cannabis authorised for fibromyalgia in France?

No. The French medical cannabis trial covers five indications — including refractory neuropathic pain and certain epilepsies — but not fibromyalgia. Medical cannabis, on prescription, is distinct from over-the-counter CBD products.

What does scientific research say about CBD and fibromyalgia?

The evidence is modest. A 2023 review judged it to be of low quality, and the most recent randomised trial, published in 2026 in 200 patients, found no effect of CBD over placebo on pain. No benefit is established.

Where does therapeutic cannabis stand in France in 2026?

The trial scheme is moving towards a regulated roll-out, with an opinion from the Haute Autorité de santé expected in 2026. It remains restricted to specific indications, on prescription, and distinct from freely sold CBD products.